Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia

  title={Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia},
  author={M S Alexander and Seema Chakravarti and Kripa Sundararajan and J M Mullin and S H Shaw and M. Blomqvist and C M Lockett},
  journal={Journal of Psychopharmacology},
  pages={276 - 282}
A controlled release (CR) formulation of remoxipride (Roxiam®, Astra) given once-daily was compared to immediate release (IR) remoxipride given twice-daily, with respect to efficacy and tolerability, in a 4-week multicentre parallel-group dose titration (200-600 mg/day) study with acutely ill schizophrenic patients. Forty- three patients received remoxipride CR (mean dose 344 mg/day) and 49 patients received remoxipride IR (mean dose 346 mg/day). Efficacy was assessed using the Kolakowska… 


A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
REM-CR was comparable in efficacy and tolerability to REM-IR, and the tolerability profile favoured both remoxipride formulations over haloperidol, and Evaluation of the clinical chemistry, haematology, and cardiovascular data showed no clinically significant deleterious effects on any organ system for either drug.
A double‐blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia
Treatment‐emergent extrapyramidal symptoms (Simpson and Angus rating) occurred statistically significantly more frequently and were more severe during haloperidol than during remoxipride CR treatment despite a statistically significantly higher concurrent use of anticholinergic drugs in the hal operidol group.
Clinical profile of remoxipride ‐ a combined analysis of a comparative double‐blind multicentre trial programme
Remoxipride seems to have a clinical profile characterized by antipsychotic efficacy in acute schizophrenia, apparently equal to that of haloperidol, and good tolerability in being non‐sedative and with low incidences of extrapyramidal, autonomic, and endocrine symptoms.
Experiences of long‐term treatment with remoxipride: efficacy and tolerability
Remoxipride can be used safely and with maintained efficacy for long‐term treatment and had a clear cut advantage concerning extrapyramidal symptoms and anticholinergic drugs were needed less frequently with remxipride than with haloperidol.
Oral versus depot medication in schizophrenia
  • D. A. Johnson
  • Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1981
It is fair to conclude that even if the two methods of administraion lead to no pharmacological differences, clinically, depot injections remain the better treatment in long‐term maintenance therapy.
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Results indicate that remoxipride is a potent, selective D2 receptor blocking agent with a preferential action in mesolimbic and extrastriatal dopamine-containing neurons.
Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily
It is concluded that Compliance with the once‐daily regimen was best, but that compliance with a twice‐ daily regimen was very similar, and both were superior to dosing three times a day.
Problems of compliance in the outpatient treatment of schizophrenia.
: The importance of treatment compliance in the outpatient care of schizophrenia is discussed, and research on this problem and on various approaches to its solution is reviewed briefly. The role of
A modification of an earlier rating scale for extrapyramidal system disturbance is described, and evidence for the validity and reliability of the scale is presented. The usefulness of the scale in
Nonparametrics: Statistical Methods Based on Ranks
Rank Tests for Comparing Two Treatments.- Comparing Two Treatments or Attributes in a Population Model.- Blocked Comparisons for Two Treatments.- Paired Comparisons in a Population Model and the